# US 2021/0171982 A1 · Improved clinical parameters by expression of factor viii

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171982 A1
- Document ID: US20210171982A1
- Status: Published application
- Kind: A1
- Application number: 17/265,750
- Filed: 2019-08-02
- Published: 2021-06-10
- Earliest claimed: 2018-08-03
- Assignees: Sangamo Therapeutics, Inc.
- Applicants: Sangamo Therapeutics, Inc.
- Inventors: Edward R. Conner; Brigit E. Riley; Didier Rouy
- Web page: https://patentgrep.com/patent/US20210171982A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/86: Viral vectors
- A61K 38/37: Factors VIII
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2750/14043: viral genome or elements thereof as genetic vector
- C12N 2750/14071: Demonstrated in vivo effect
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein are constructs used for liver-specific expression of a transgene.

## Claims

### Claim 1

A method of increasing Factor VIII (FVIII) protein in a human subject, comprising administering to the human subject one or more doses of 5×1012 to 5×1013 vg/kg of an Adenovirus-Associated Virus (AAV) vector that encodes a FVIII protein, wherein administration of the AAV vector results in a clinically relevant increase in the level of circulating FVIII activity.

### Claim 2

A method of increasing Factor VIII (FVIII) protein in a human subject, comprising administering to the human subject one or more doses of 5×1012 to 5×1013 vg/kg of an Adenovirus-Associated Virus (AAV) vector that encodes a FVIII protein, wherein administration of the AAV vector results in a reduction of the number of FVIII treatments the human subject undergoes.

### Claim 3 (depends on 1)

The method of claim 1, wherein administration of the AAV vector results in one or zero occurrence of spontaneous bleeding episodes in the human subject between 3-12 months after administration.

### Claim 4 (depends on 1)

The method of claim 1, comprising administering one or more doses of 1×1013 vg/kg to 3×1013 vg/kg of the AAV vector.

### Claim 5 (depends on 1)

The method of claim 1, comprising administering one or more doses of 2×1013 vg/kg to 4×1013 vg/kg of the AAV vector.

### Claim 6 (depends on 1)

The method of claim 1, comprising administering one or more doses of 3×1013 vg/kg of the AAV vector.

### Claim 7 (depends on 1)

The method of claim 1, wherein the FVIII protein comprises the amino acid sequence of SEQ ID NO:1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the AAV vector has an AAV6 serotype.

### Claim 9 (depends on 8)

The method of claim 8, wherein the AAV vector comprises an expression cassette comprising a polynucleotide that encodes the FVIII protein operably linked to a liver-specific enhancer and a promoter.

### Claim 10 (depends on 9)

The method of claim 9, wherein the liver-specific enhancer comprises the nucleotide sequence of SEQ ID NO:2 and/or the promoter comprises the nucleotide sequence of SEQ ID NO:3.

### Claim 11 (depends on 8)

The method of claim 8, wherein the AAV vector comprises an AAV2 5′ inverted terminal repeat (ITR) sequence and an AAV2 3′ ITR sequence that flank the expression cassette.

### Claim 12 (depends on 8)

The method of claim 8, wherein the AAV2 5′ ITR comprises the nucleotide sequence of SEQ ID NO:12 and/or the AAV2 3′ITR comprises the nucleotide sequence of SEQ ID NO:13.

### Claim 13 (depends on 8)

The method of claim 8, wherein the expression cassette comprises the nucleotide sequence of SEQ ID NO:5.

### Claim 14 (depends on 1)

The method of claim 1, wherein the human subject has hemophilia.

### Claim 15 (depends on 2)

The method of claim 2, wherein the human subject does not receive any FVIII treatments 3-12 months after administration.

### Claim 16 (depends on 2)

The method of claim 2, wherein administration of the AAV vector results in one or zero occurrence of spontaneous bleeding episodes in the human subject between 3-12 months after administration.

### Claim 17 (depends on 2)

The method of claim 2, comprising administering one or more doses of 1×1013 vg/kg to 3×1013 vg/kg of the AAV vector.

### Claim 18 (depends on 2)

The method of claim 2, comprising administering one or more doses of 2×1013 vg/kg to 4×1013 vg/kg of the AAV vector.

### Claim 19 (depends on 2)

The method of claim 2, comprising administering one or more doses of 3×1013 vg/kg of the AAV vector.

### Claim 20 (depends on 2)

The method of claim 2, wherein the FVIII protein comprises the amino acid sequence of SEQ ID NO: 1.
